 |
1 Product |  |
11 Diseases | | 1 Product |
|
6 Trials |  |
202 News |  |
| «12345 |
- gedatolisib (PF-05212384) / Celcuity
Trial completion: Investigation Of The Metabolism, And Excretion Of [14c]-PF-05212384 In Healthy Male Volunteers (clinicaltrials.gov) - Aug 28, 2014
P1, N=6, Completed, Sponsor: Pfizer
Active, not recruiting --> Completed
- ||| gedatolisib (PF-05212384) / Celcuity
Trial initiation date, Metastases: A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer (clinicaltrials.gov) - Aug 11, 2014
P2, N=159, Recruiting, Sponsor: Pfizer
Active, not recruiting --> Completed Initiation date: Apr 2014 --> Nov 2013
- gedatolisib (PF-05212384) / Celcuity
Enrollment closed: Investigation Of The Metabolism, And Excretion Of [14c]-PF-05212384 In Healthy Male Volunteers (clinicaltrials.gov) - Aug 4, 2014
P1, N=6, Active, not recruiting, Sponsor: Pfizer
Initiation date: Apr 2014 --> Nov 2013 Not yet recruiting --> Active, not recruiting
- ||| gedatolisib (PF-05212384) / Celcuity
Trial initiation date, Metastases: A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer (clinicaltrials.gov) - Jul 14, 2014
P2, N=159, Recruiting, Sponsor: Pfizer
Not yet recruiting --> Active, not recruiting Initiation date: Nov 2013 --> Apr 2014
- gedatolisib (PF-05212384) / Celcuity
New P1 trial: Investigation Of The Metabolism, And Excretion Of [14c]-PF-05212384 In Healthy Male Volunteers (clinicaltrials.gov) - May 18, 2014
P1, N=6, Not yet recruiting, Sponsor: Pfizer
- gedatolisib (PF-05212384) / Celcuity
Enrollment open, Metastases: IOSI-NDU-001: Dose Finding Study Of PF-05212384 With Paclitaxel And Carboplatin In Patients With Advanced Solid Tumor (clinicaltrials.gov) - Apr 8, 2014
P1, N=40, Recruiting, Sponsor: Cristiana Sessa
Initiation date: Nov 2013 --> Apr 2014 Not yet recruiting --> Recruiting
- | PF-04691502 / Pfizer, gedatolisib (PF-05212384) / Celcuity
Trial termination: A Study Of Two Dual PI3K/mTOR Inhibitors, PF-04691502 And PF-05212384 In Patients With Recurrent Endometrial Cancer (clinicaltrials.gov) - Mar 27, 2014
P2, N=67, Terminated, Sponsor: Pfizer
Not yet recruiting --> Recruiting Recruiting --> Terminated; See termination reason in detailed description.
- PF-04691502 / Pfizer, gedatolisib (PF-05212384) / Celcuity
Enrollment change: A Study Of Two Dual PI3K/mTOR Inhibitors, PF-04691502 And PF-05212384 In Patients With Recurrent Endometrial Cancer (clinicaltrials.gov) - Mar 27, 2014
P2, N=67, Terminated, Sponsor: Pfizer
Recruiting --> Terminated; See termination reason in detailed description. N=144 --> 67
- |||| gedatolisib (PF-05212384) / Celcuity
Enrollment open, Metastases: A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer (clinicaltrials.gov) - Mar 11, 2014
P1/2, N=180, Recruiting, Sponsor: Pfizer
N=144 --> 67 Not yet recruiting --> Recruiting
- gedatolisib (PF-05212384) / Celcuity
New P1 trial, Metastases: IOSI-NDU-001: Dose Finding Study Of PF-05212384 With Paclitaxel And Carboplatin In Patients With Advanced Solid Tumor (clinicaltrials.gov) - Feb 20, 2014
P1, N=40, Recruiting, Sponsor: Cristiana Sessa
- |||| gedatolisib (PF-05212384) / Celcuity
Enrollment open, Metastases: A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer (clinicaltrials.gov) - Dec 1, 2013
P2, N=159, Recruiting, Sponsor: Pfizer
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| gedatolisib (PF-05212384) / Celcuity
Enrollment open, Combination therapy: A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC) (clinicaltrials.gov) - Sep 25, 2013
P1b, N=85, Recruiting, Sponsor: Pfizer
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||||| gedatolisib (PF-05212384) / Celcuity
New P1/2 trial, Metastases: A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer (clinicaltrials.gov) - Sep 6, 2013
P1/2, N=180, Recruiting, Sponsor: Pfizer
- ||||| gedatolisib (PF-05212384) / Celcuity
New P2 trial, Metastases: A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer (clinicaltrials.gov) - Aug 15, 2013
P2, N=159, Recruiting, Sponsor: Pfizer
- || PF-04691502 / Pfizer, gedatolisib (PF-05212384) / Celcuity
Enrollment change, Combination therapy, Metastases: Clinical Study Of PI3K/mTOR Inhibitors In Combination With An Oral MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer (clinicaltrials.gov) - Nov 25, 2012
P1, N=120, Recruiting, Sponsor: Pfizer
Not yet recruiting --> Recruiting N=100 --> 120
- ||| gedatolisib (PF-05212384) / Celcuity
Trial completion: Study of PF-05212384 (Also Known as PKI-587)Administered Intravenously To Subjects With Solid Tumors (clinicaltrials.gov) - Nov 7, 2012
P1, N=78, Completed, Sponsor: Pfizer
N=100 --> 120 Active, not recruiting --> Completed
- ||| PF-04691502 / Pfizer, gedatolisib (PF-05212384) / Celcuity
Enrollment open, Combination therapy, Metastases: Clinical Study Of PI3K/mTOR Inhibitors In Combination With An Oral MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer (clinicaltrials.gov) - Nov 15, 2011
P1, N=120, Recruiting, Sponsor: Pfizer
Active, not recruiting --> Completed Not yet recruiting --> Recruiting